Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching
Anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy regimens offers a good survival benefit for patients with advanced non-small-cell lung cancer who fail to respond to standard therapy. When both efficacy and safety are considered, a combination of anti-angiogenic agents, ICIs, and platinum-containing chemotherapy can be used as a choice for the treatment of advanced NSCLC.
Authors
- Chaojun Xue
- Haotian Yang
- Bingnan Ren (ORCID: https://orcid.org/0000-0003-2651-1637)
- Ze Yu (ORCID: https://orcid.org/0000-0002-4727-8427)
- Yin Wu (ORCID: https://orcid.org/0000-0002-7414-3827)
- Xuejia Qiu (ORCID: https://orcid.org/0000-0002-3198-5370)
- Xiao Li (ORCID: https://orcid.org/0000-0002-5531-1426)
- Jinyuan Zhang (ORCID: https://orcid.org/0000-0002-5072-4934)
- Yue Zhao (ORCID: https://orcid.org/0000-0001-5694-7904)
- Zhenghao Wang (ORCID: https://orcid.org/0000-0003-3411-3276)
Institutions
- Hebei General Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-25
- DOI
- https://doi.org/10.3389/fonc.2024.1446950
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00